Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT adjuvant erlotinib after resection in EGFR-positive NSCLC
2005-001747-29Phase 3Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tarceva with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Sep 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001747-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001747-29.